Tower Research Capital (TRC)’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,193
| Closed | -$1.6K | – | 5576 |
|
|
2026
Q1 | $1.6K | Buy |
+2,193
| New | +$9.98K | ﹤0.01% | 4632 |
|
|
2025
Q4 | – | Sell |
-1,121
| Closed | -$8.26K | – | 5521 |
|
|
2025
Q3 | $8.26K | Buy |
1,121
+1,050
| +1,479% | +$8.92K | ﹤0.01% | 4054 |
|
|
2025
Q2 | $543 | Sell |
71
-341
| -83% | -$5.31K | ﹤0.01% | 4997 |
|
|
2025
Q1 | $7.87K | Sell |
412
-927
| -69% | -$29.1K | ﹤0.01% | 3927 |
|
|
2024
Q4 | $48.5K | Buy |
1,339
+1,198
| +850% | +$33.4K | ﹤0.01% | 2573 |
|
|
2024
Q3 | $4.06K | Buy |
141
+121
| +605% | +$2.69K | ﹤0.01% | 4692 |
|
|
2024
Q2 | $499 | Buy |
+20
| New | +$909 | ﹤0.01% | 5314 |
|
|
2024
Q1 | – | Sell |
-1,902
| Closed | -$196K | – | 6100 |
|
|
2023
Q4 | $196K | Buy |
+1,902
| New | +$171K | ﹤0.01% | 2109 |
|
|
2023
Q3 | – | Sell |
-555
| Closed | -$65.1K | – | 6184 |
|
|
2023
Q2 | $65.1K | Buy |
555
+479
| +630% | +$60.7K | ﹤0.01% | 2365 |
|
|
2023
Q1 | $6K | Sell |
76
-426
| -85% | -$37.2K | ﹤0.01% | 4867 |
|
|
2022
Q4 | $43K | Buy |
502
+288
| +135% | +$22K | ﹤0.01% | 2470 |
|
|
2022
Q3 | $7K | Sell |
214
-131
| -38% | -$3.62K | ﹤0.01% | 4921 |
|
|
2022
Q2 | $8K | Buy |
345
+323
| +1,468% | +$11.3K | ﹤0.01% | 4702 |
|
|
2022
Q1 | $1K | Sell |
22
-169
| -88% | -$6.74K | ﹤0.01% | 5849 |
|
|
2021
Q4 | $11K | Buy |
+191
| New | +$13.6K | ﹤0.01% | 4447 |
|
|
2021
Q3 | – | Sell |
-624
| Closed | -$61K | – | 6111 |
|
|
2021
Q2 | $61K | Buy |
624
+520
| +500% | +$52.4K | ﹤0.01% | 2862 |
|
|
2021
Q1 | $12K | Buy |
104
+101
| +3,367% | +$16.8K | ﹤0.01% | 4274 |
|
|
2020
Q4 | $1K | Sell |
3
-2
| -40% | -$405 | ﹤0.01% | 5029 |
|
|
2020
Q3 | $1K | Hold |
5
| – | – | ﹤0.01% | 4728 |
|
|
2020
Q2 | $1K | Hold |
5
| – | – | ﹤0.01% | 4635 |
|
|
2020
Q1 | $1K | Buy |
+5
| New | +$1.05K | ﹤0.01% | 2830 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 4193 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4208 |
|
Other funds holding RVPH
Tower Research Capital (TRC)'s RVPH Position: Q2 2026 in Review
Tower Research Capital (TRC) sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2026, closing a stake of 2,193 shares — an estimated $1.6K sold.
Tower Research Capital (TRC) first reported a position in RVPH in Q1 2020 and held it in 21 quarters. The position peaked at $196K in Q4 2023. 5 funds tracked by Wall St. Rank hold RVPH as of Q2 2026.
- Tower Research Capital (TRC) reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,193 REVIVA PHARMA HLDGS INC shares in Q2 2026, an estimated $1.6K.
- Tower Research Capital (TRC) first reported a position in REVIVA PHARMA HLDGS INC in Q1 2020 and held it in 21 quarters.
- Tower Research Capital (TRC)'s REVIVA PHARMA HLDGS INC position peaked at $196K in Q4 2023.
- 5 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.